Stay updated on AK104 Plus Anlotinib in NSCLC Clinical Trial

Sign up to get notified when there's something new on the AK104 Plus Anlotinib in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the AK104 Plus Anlotinib in NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A notice appears announcing NIH website changes and explaining that some federal agency content may use “Super Intelligence” in place of “Artificial Intelligence.”
    Difference
    0.8%
    Check dated 2026-10-24T19:13:13.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The site footer’s revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-17T20:14:12.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov site revision changed from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-10T20:40:52.000Z thumbnail image
  4. Check
    36 days ago
    Change Detected
    Summary
    A new revision entry v3.7.0 has been added to the study's history, while the older revision v3.6.6 has been removed. This indicates ongoing updates to the study record.
    Difference
    0.1%
    Check dated 2026-09-19T20:34:27.000Z thumbnail image
  5. Check
    57 days ago
    Change Detected
    Summary
    A new site release label Revision: v3.6.6 was added to the history, and the previous label Revision: v3.6.5 was removed, reflecting an update to the release notes shown in the history view.
    Difference
    0.1%
    Check dated 2026-08-29T18:49:38.000Z thumbnail image
  6. Check
    78 days ago
    Change Detected
    Summary
    A new revision entry, Revision: v3.6.5, is added to the study history. The previous entry, Revision: v3.6.4, is removed.
    Difference
    0.1%
    Check dated 2026-08-08T09:53:18.000Z thumbnail image

Stay in the know with updates to AK104 Plus Anlotinib in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the AK104 Plus Anlotinib in NSCLC Clinical Trial page.